Allergens of &lt;b&gt;&lt;i&gt;Blomia tropicalis&lt;/i&gt;&lt;/b&gt;: An Overview of Recombinant Molecules

Silva, Eduardo Santos da; Asam, Claudia; Lackner, Peter; Hofer, Heidi; Wallner, Michael; Pinheiro, Carina S.; Alcântara-Neves, Neuza Maria; Ferreira, Fátima

doi:10.1159/000464325

Cited by 37 publications

(38 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Here we showed that short-term treatment with low dose of allergens and CpG efficiently reduced key features of allergic asthma. In addition, we also evaluated whether this type of immunotherapy could be applied to a relevant respiratory allergens obtained from B. tropicalis mite extract, one of the most prevalent mites in tropical countries (78) and found that the treatment with co-encapsulated Bt allergens and CpG reversed the established allergic lung responses. These results demonstrate the potential applications of our formulation to different allergens and highlight the importance of correct diagnosis for developing a specific allergen treatment (79).…”

Section: Discussionmentioning

confidence: 99%

Allergen-Specific Immunotherapy With Liposome Containing CpG-ODN in Murine Model of Asthma Relies on MyD88 Signaling in Dendritic Cells

et al. 2020

View full text Add to dashboard Cite

Changing the immune responses to allergens is the cornerstone of allergen immunotherapy. Allergen-specific immunotherapy that consists of repeated administration of increasing doses of allergen extract is potentially curative. The major inconveniences of allergen-specific immunotherapy include failure to modify immune responses, long-term treatment leading to non-compliance and the potential for developing life-threating anaphylaxis. Here we investigated the effect of a novel liposomal formulation carrying low dose of allergen combined with CpG-ODN, a synthetic TLR9 agonist, on established allergic lung inflammation. We found that challenge with allergen (OVA) encapsulated in cationic liposome induced significantly less severe cutaneous anaphylactic reaction. Notably, short-term treatment (three doses) with a liposomal formulation containing co-encapsulated allergen plus CpG-ODN, but not allergen or CpG-ODN alone, reversed an established allergic lung inflammation and provided long-term protection. This liposomal formulation was also effective against allergens derived from Blomia tropicalis mite extract. The attenuation of allergic inflammation was not associated with increased numbers of Foxp3-positive or IL-10-producing regulatory T cells or with increased levels of IFN-gamma in the lungs. Instead, the anti-allergic effect of the liposomal formulation was dependent of the innate immune signal transduction generated in CD11c-positive putative dendritic cells expressing MyD88 molecule. Therefore, we highlight the pivotal role of dendritic cells in mediating the attenuation of established allergic lung inflammation following immunotherapy with a liposomal formulation containing allergen plus CpG-ODN.

show abstract

Section: Discussionmentioning

confidence: 99%

Allergen-Specific Immunotherapy With Liposome Containing CpG-ODN in Murine Model of Asthma Relies on MyD88 Signaling in Dendritic Cells

et al. 2020

View full text Add to dashboard Cite

show abstract

“…It is necessary to emphasize that the Blo t 5 molecule has a low cross-reactivity with the Der p 5 allergen and can be suggested as asthma biomarker in tropical regions [120]. The same study showed that true co-sensitization to D. pteronyssinus and Blomia allergens resulted in a higher risk of asthma.…”

Section: Mite Allergens and Asthmamentioning

confidence: 97%

Protein Biomarkers in Asthma

Karaulov

Garib

et al. 2018

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Asthma is a chronic disabling respiratory disease that can be triggered by a variety of factors, including allergens, respiratory infections, psychological factors, occupational agents, exercise, atmospheric pollutants, and drugs. The asthma syndrome has been treated for decades according to a “one-fits-all” treatment strategy based on bronchodilators and steroids. With the availability of new forms of treatment targeting the different pathomechanisms of the asthma syndrome, such as anti-immunoglobulin E and cytokine-targeting therapies, the interest in biomarkers that can dis criminate different forms of asthma according to their pathomechanisms has increased. This review attempts to provide an overview of protein biomarkers in asthma and how they might be used to discriminate different forms of asthma that may respond positively to sophisticated new targeted therapies.

show abstract

“…Blo t 5 and Blo t 21 share a moderate degree of homology, but the IgE cross-reactivity between the 2 allergens is very limited [24-26]. Thus, Blo t 5 or Blo t 21 are defined as BTMA [27, 28]. In this study, the BTMA+ group, with specific IgE to either Blo t 5 or Blo t 21, was denoted as “co-sensitized”; the BTMA– group, where patients had no detectable IgE to neither Blo t 5 nor Blo t 21, was denoted as “cross-reactive” to DP.…”

Section: Introductionmentioning

confidence: 99%

Clinical Response to Subcutaneous Dermatophagoides pteronyssinus Immunotherapy in Children with Allergic Rhinitis and Asthma Is Independent of Sensitization to Blomia tropicalis Allergens

Shi

Zheng²,

Chen

et al. 2018

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: Dermatophagoides pteronyssinus (DP) and Blomia tropicalis (BT) are the dominant house dust mites inducing allergic diseases in tropical climates. It is not known whether the efficacy of DP subcutaneous immunotherapy (SCIT) is similar in patients sensitized to DP alone or to both DP and BT. Method: Ninety-five children (5–17 years old) affected by asthma with rhinitis and sensitized to both DP and BT received 3 years of DP-SCIT. Clinical symptom and medication scores, serum-specific IgE and IgG₄ were evaluated during DP-SCIT. Patients were grouped based on DP and BT co-sensitization or cross-reactivity, according to positive or negative IgE to BT major allergen (BTMA). Results: After 3 years of DP-SCIT, all patients had significant reductions in symptoms and medication use. In all, 65% of the patients were free of asthma symptoms and medication use; in addition, 3% was free of rhinitis symptoms. FEV₁ in all patients were greater than 95% of predicted. DP-SCIT induced significant increases in DP- and BT-specific IgG₄. In 50% of patients, DP-specific IgG₄ increased more than 67-fold. BT-specific IgG₄ increased more than 2.5 fold. A moderate correlation (r = 0.48–0.61, p < 0.01) was found between specific IgE against DP and BT in the BTMA– group (n = 34) before and after DP-SCIT, whereas no correlation was found in the BTMA+ group (n = 61). The 2 BTMA groups responded similarly with regard to clinical improvement and increase in specific IgG₄ to both DP and BT. No safety finding of concern were reported in either group. Conclusion: DP-SCIT may be of clinical benefit to patients with IgE sensitizations to both DP and BT. DP-SCIT induces IgG₄ that cross-react with BT allergens.

show abstract

Allergens of <b><i>Blomia tropicalis</i></b>: An Overview of Recombinant Molecules

Cited by 37 publications

References 99 publications

Allergen-Specific Immunotherapy With Liposome Containing CpG-ODN in Murine Model of Asthma Relies on MyD88 Signaling in Dendritic Cells

Allergen-Specific Immunotherapy With Liposome Containing CpG-ODN in Murine Model of Asthma Relies on MyD88 Signaling in Dendritic Cells

Protein Biomarkers in Asthma

Clinical Response to Subcutaneous <b><i>Dermatophagoides pteronyssinus</i></b> Immunotherapy in Children with Allergic Rhinitis and Asthma Is Independent of Sensitization to <b><i>Blomia tropicalis</i></b> Allergens

Contact Info

Product

Resources

About